named programs · 4 · from sources
What they call their work
CAPA Consortium
Cohorts for Alzheimer's Prevention Action (CAPA) supports collaborative research to identify and validate biomarkers and interventions for Alzheimer's prevention.
Cognitive Vitality Program
Public education initiative at cognitivevitality.org providing science-based information on brain health, prevention strategies, and lifestyle factors affecting cognitive decline.
Research Grant Program
Funds drug discovery and development research for Alzheimer's disease and related dementias through a competitive peer-reviewed process.
The Treat FTD Fund
Funds preclinical and clinical research to develop treatments for frontotemporal dementia (FTD), a related neurodegenerative condition.
activities · 3 groups
What they do
-
Alzheimer's Research and Support Services 4 activities
- Advisory panels for Alzheimer's therapy developmentOrganizes advisory panels and funds related research to accelerate the development of therapies for Alzheimer's prevention and treatment.
- Alzheimer's drug discovery and development research fundingFunds translational research programs in academia and biotechnology companies globally, with a focus on drug development, clinical trials, biomarkers, and prevention of Alzheimer's disease. Has awarded nearly $400 million to support 792 Alzheimer's drug development, biomarker, and prevention programs across 21 countries.
- Diagnostics Accelerator initiative for Alzheimer's precision medicineLaunched and advanced a Diagnostics Accelerator initiative to promote precision medicine in Alzheimer's disease, supporting innovation in diagnostic tools and approaches.
- Melvin R. Goodes Prize for Alzheimer's research excellenceAwards the Melvin R. Goodes Prize to recognize outstanding contributions to Alzheimer's drug discovery research, including to pioneers such as Randall J. Bateman, MD, and Miranda E. Orr, PhD.
-
-
Medical Research & Education Dissemination 1 activity
- Publication and dissemination of Alzheimer's research findingsConducts scientific evaluations of Alzheimer's and cognitive-aging prevention therapies and disseminates findings through public platforms like Cognitive Vitality and peer-reviewed publications. Publishes the Alzheimer's Clinical Trials Report to track and analyze clinical trials in Alzheimer's disease and released a landmark paper on biomarker use across Alzheimer’s clinical trials.
-
-
Patient and Researcher Conferences 1 activity
- Scientific conferences and networking events for Alzheimer's researchersOrganizes and sponsors global scientific conferences and events, such as the 2022 ADDF Goodes Prize Luncheon in New York City, to facilitate knowledge sharing, collaboration, and partnership development among Alzheimer's researchers and industry professionals.
-
financials · form 990 · fy2024
revenue
Total revenue$47.28M
Contributions & grants$36.05M76%
Program service revenue$5.84M12%
Investment income$5.53M12%
Other revenue$-138K
expenses
Total expenses$88.25M
Program expenses93%
Admin / overhead3%
Fundraising4%
Salaries & benefits$8.86M
Grants paid out$73.25M
Largest expense lineCompensation
balance sheet
Total assets$299.39M
Cash$54.92M
Investments$70.62M
Liabilities$82.42M
Net assets$216.98M
Liquid reserves17.1 mo
3 years on record · 2020–2024 · YoY revenue +25.3%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 8
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| HOWARD FILLIT MD | FOUNDING EXEC. DIR. & CHIEF SCIENCE OFF. | 40 | $698K |
| MARK ROITHMAYR | CEO | 40 | $692K |
| LAURA NISENBAUM | EXECUTIVE DIRECTOR, DRUG DEVELOPMENT | 40 | $480K |
| KAREN HARRIS | CFO AND HEAD OF MISSION RELATED INV | 40 | $395K |
| JANE MCINTOSH | CHIEF EXTERNAL AFFAIRS | 40 | $392K |
| AARON BURSTEIN | HEAD OF SEARCH AND EVALUATION | 40 | $368K |
| ELI SHOBIN | SENIOR DIRECTOR DXA | 40 | $270K |
| LAKITA CAVIN | ATTORNEY, MISSION-RELATED | 40 | $241K |
board members · 17
- ADAM HOFFMAN — GOVERNOR
- ALICE SHURE — GOVERNOR
- ANN JACKSON — GOVERNOR
- BONNIE ENGLEBARDT LAUTENBERG — GOVERNOR
- BONNIE PFEIFER EVANS — GOVERNOR
- CAROL BOULANGER — GOVERNOR
- DAVID WEINREB — GOVERNOR
- GARY M LAUDER — GOVERNOR
- HENRIK ZETTERBERG MD PHD — GOVERNOR
- JULIEANN SHANAHAN CFA — GOVERNOR
- LANNY EDELSOHN MD — GOVERNOR
- LAURA STEELE — GOVERNOR
- LAURENCE LEEDS JR — GOVERNOR
- LEONARD LAUDER — CO-CHAIRMAN /GOVERNOR (DECEASED)
- MIIA KIVIPELTO MD PHD — GOVERNOR
- NANCY CORZINE — GOVERNOR
- NANCY GOODES — GOVERNOR
relationships · 10
Who they work with
- Bill & Melinda Gates Foundation Partner — Engages in shared advocacy and public awareness efforts in the fight against Alzheimer's disease.
- Biogen Partner — Collaborates on research related to tau-targeting therapies in Alzheimer's disease.
- Cognitive Vitality Partner — Affiliated website administered by the Alzheimer’s Drug Discovery Foundation providing related content.
- Cognitive Vitality Partner — Platform used to share scientific findings on Alzheimer's and cognitive-aging prevention.
- Leonard A. Lauder Partner — Co-Founder and Chairman Emeritus of the Alzheimer's Drug Discovery Foundation
- Leonard A. Lauder Partner — Co-founder and former co-chairman of the Alzheimer's Drug Discovery Foundation.
- Leonard A. and Ronald S. Lauder Partner — Founded the Alzheimer's Drug Discovery Foundation in 1998
- Ronald S. Lauder Partner — Co-Founder and Chairman of the Alzheimer's Drug Discovery Foundation
- Target ALS Foundation Partner — Collaborates on the Diagnostics Accelerator: Biomarker Discovery RFP to advance biomarker research for neurodegenerative diseases.
- Wake Forest University School of Medicine Partner — Host institution of 2022 Melvin R. Goodes Prize winner Miranda E. Orr, PhD, recognized at the ADDF Goodes Prize Luncheon.
strategies · 3
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Scientific Collaboration through Recognitionmethodology: scientific recognition and collaborationBy recognizing leading researchers with the Melvin R. Goodes Prize and convening them, we accelerate Alzheimer's progress, because scientific recognition fosters collaboration and knowledge exchange that catalyzes innovation.
- Translational Research Accelerationmethodology: translational_research_accelerationBy funding high-risk, early-stage translational research and clinical trials, we accelerate the development of Alzheimer's drugs, because this bridges the gap between basic science and pharmaceutical investment, enabling promising biology to become viable drug candidates.
- Venture Philanthropy for Breakthrough Researchmethodology: venture_philanthropyBy applying a venture philanthropy model to fund innovative Alzheimer's research in academia and biotech, we generate breakthroughs, because this approach allows strategic, flexible investment in high-potential, high-risk science that traditional funders often avoid.